ClinicalTrials.gg
CompletedNCT01154036Updated Feb 9, 2022Results posted

MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)

A Phase 3 interventional study of ezetimibe 10 mg and atorvastatin in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2022-02-09.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,547
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
2nd of 97
1,547 · median 148
Started
2010
the only one that year
Phase 3
50 of 98
1 open now
Registered
63rd of 98
by date
Lead sponsor
55 of 98
Organon and Co

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 2nd largest by enrollment of the 97 interventional ones that give a count, is the only one that started in 2010, is one of 50 in phase 3, and was the 63rd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

This study will compare the lipid-altering efficacy and safety of switching to co-administration of ezetimibe and atorvastatin versus treatment with atorvastatin or rosuvastatin in high cardiovascular risk patients with hypercholesterolemia who have not achieved specified low-density lipoprotein cholesterol (LDL-C) levels. The primary hypothesis is that the co-administration of ezetimibe 10 mg and atorvastatin 10 mg will be superior to both atorvastatin 20 mg and rosuvastatin 10 mg with respect to the percentage reduction in low-density lipoprotein-cholesterol (LDL-C) after 6 weeks of treatment.

Read the detailed description

This is a 18 week randomized, double-blind, active-controlled, multicenter study composed of a 6 week screening/run-in and 12 week double-blind treatment period (composed of 2 phases; each 6 weeks in duration). Only those participants who do not meet low density lipoprotein-cholesterol (LDL-C) goals at the end of Phase I (Week 6), were eligible to continue into Phase II (Week 12).

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is at high cardiovascular risk and meets one of the following conditions: has never taken lipid-lowering therapy or has been off such therapy for at least 6 weeks; or, is currently taking a stable dose of certain lipid-lowering agents
  • Patient is willing to maintain a cholesterol lowering diet during the study
  • Female patients receiving non-cyclical hormone therapy have maintained a stable dose and regimen for at least 8 weeks and are willing to continue the same regimen during the study

Exclusion criteria

Exclusion Criteria:

  • Patient is Asian
  • Patient routinely has more than 2 alcoholic drinks per day
  • Female patient is pregnant or breastfeeding
  • Patient has congestive heart failure
  • Patient has had a myocardial infarction, coronary bypass surgery, angioplasty, or acute coronary syndrome within 3 months of screening
  • Patient has uncontrolled cardiac arrhythmias
  • Patient has had a partial ileal or gastric bypass or other significant intestinal malabsorption
  • Patient has uncontrolled high blood pressure
  • Patient has kidney disease
  • Patient has any disease known to influence blood lipid levels
  • Patient has any disorders of the blood, digestive system, or nervous system including stroke and degenerative disease that would limit study participation
  • Patient has poorly controlled or newly diagnosed diabetes
  • Patient is known to be positive
  • Patient has a history of cancer in the last 5 years, except certain skin and cervical cancers
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,547 participants (actual)

Study arms

  • Experimental
    Phase I: ezetimibe (EZ) 10 mg + atorvastatin (Atorva) 10 mg

    Co-administration of EZ 10 mg tablet + Atorva 10 mg tablet; once daily for 6 weeks

    Drug: ezetimibe 10 mg · Drug: atorvastatin

  • Active comparator
    Phase I: Atorvastatin 20 mg

    Atorvastatin 20 mg tablet once daily for 6 weeks

    Drug: atorvastatin

  • Active comparator
    Phase I: Rosuvastatin 10 mg

    Rosuvastatin 10 mg tablet once daily for 6 weeks

    Drug: Comparator: rosuvastatin

  • Experimental
    Phase II: EZ 10mg+Atorva 10mg

    Participants who had previously received EZ 10 mg + Atorva 10 mg in Phase I and continued on EZ 10 mg + Atorva 10 mg once daily for 6 weeks during Phase II regardless of whether or not LDL-C goals were achieved in Phase I

    Drug: ezetimibe 10 mg · Drug: atorvastatin

  • Experimental
    Phase II: EZ 10mg + Atorva 20mg [A]

    Participants who had previously received Atorva 20 mg in Phase I and did not reach LDL-C goal and were switched to EZ 10 mg + Atorva 20 mg once daily for 6 weeks in Phase II

    Drug: ezetimibe 10 mg · Drug: atorvastatin

  • Active comparator
    Phase II: Atorva 40mg

    Participants who had previously received Atorva 20 mg in Phase I and did not reach LDL-C goal and were switched Atorva 40 mg once daily for 6 weeks in Phase II

    Drug: atorvastatin

  • Experimental
    Phase II: EZ 10mg + Atorva 20mg [R]

    Participants who had previously received Rosuvastatin 10 mg in Phase I and did not reach LDL-C goal and received EZ 10 mg + Atorva 20 mg once daily for 6 weeks in Phase II

    Drug: ezetimibe 10 mg · Drug: atorvastatin

  • Active comparator
    Phase II: Rosuvastatin 20mg

    Participants who had previously received Rosuvastatin 10 mg in Phase I and did not reach LDL-C goal and were switched to Rosuvastatin 20 mg once daily for 6 weeks in Phase

    Drug: Comparator: rosuvastatin

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I)

    LDL-C levels measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4. LDL-C was calculated using the Friedewald method when triglyceride (TG)\<350 mg/dL (3.95 mmol/L) and beta quantification ultracentrifugation when TG≥350 mg/dL (3.95 mmol/L).

    Time frame: Baseline and Week 6 (end of Phase I )

Secondary outcomes

  1. Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase II).

    LDL-C levels measured at Baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12). Baseline was defined as the average of the values at Visits 5 and 6. LDL-C was calculated using the Friedewald method when triglyceride (TG)\<350 mg/dL (3.95 mmol/L) and beta quantification ultracentrifugation when TG ≥350 mg/dL (3.95 mmol/L).

    Time frame: Baseline (Week 6) and Week 12

  2. Percentage of Participants That Reach Target LDL-C Level of < 100 mg/dL (Phase I)

    Time frame: Week 6 (End of Phase I)

  3. Percentage of Participants That Reach Target LDL-C Level of < 100 mg/dL (Phase II)

    Time frame: Week 12 (End of Phase II)

  4. Percentage of Participants That Reach Target LDL-C Level of < 70 mg/dL (Phase I)

    Time frame: Week 6 (End of Phase I)

  5. Percentage of Participants That Reach Target LDL-C Level of < 70 mg/dL (Phase II)

    Time frame: Week 12 (end of Phase II)

  6. Percent Change From Baseline in Total Cholesterol (TC) (Phase I)

    TC measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4

    Time frame: Baseline and Week 6 (end of Phase I)

  7. Percent Change From Baseline in Total Cholesterol (TC) (Phase II)

    TC levels measured at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.

    Time frame: Baseline (Week 6; end of Phase I) and Week 12 (end of Phase II)

  8. Percent Change From Baseline in Triglycerides (TG) (Phase I)

    TG measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4. Baseline and post-baseline measurements were log-transformed in the response vector, with fixed effects for treatment, time and the interaction of time by treatment.

    Time frame: Baseline and Week 6 (end of Phase I)

  9. Percent Change From Baseline in Triglycerides (TG) (Phase II)

    TG levels measured at Baseline (Week 6: end of Phase I) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6. Baseline and post-baseline measurements were log-transformed in the response vector, with fixed effects for treatment, time and the interaction of time by treatment.

    Time frame: Baseline (Week 6; end of Phase I) and Week 12 (end of Phase II)

  10. Percent Change From Baseline in High-density Lipoprotein-Cholesterol (HDL-C) (Phase I)

    HDL-C measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4

    Time frame: Baseline and Week 6 (end of Phase I)

  11. Percent Change From Baseline in HDL-C (Phase II)

    HDL-C levels measured at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.

    Time frame: Baseline (Week 6; end of Phase I) and Week 12 (end of Phase II)

  12. Percent Change From Baseline in Apolipoprotein B (Apo B) (Phase I)

    Apo-B measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4

    Time frame: Baseline and Week 6 (end of Phase I)

  13. Percent Change From Baseline in Apo B (Phase II)

    Apo-B levels measured at Baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.

    Time frame: Baseline (Week 6; end of Phase 1) and Week 12 (end of Phase II)

  14. Percent Change From Baseline in Apolipoprotein A-I (Apo A-I) (Phase I)

    Apo-A-I measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4

    Time frame: Baseline and Week 6 (end of Phase I)

  15. Percent Change From Baseline in Apo A-I (Phase II)

    Apo-A-I levels measured at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.

    Time frame: Baseline (Week 6; end of Phase I) and Week 12 (end of Phase II)

  16. Percent Change From Baseline in Non-HDL-C (Phase I)

    Non-HDL-C measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4

    Time frame: Baseline and Week 6 (end of Phase I)

  17. Percent Change From Baseline in Non-HDL-C (Phase II)

    Non-HDL-C levels calculated at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.

    Time frame: Baseline (Week 6; end of Phase I) and Week 12 (end of Phase II)

  18. Percent Change From Baseline in TC/HDL-C Ratio (Phase I)

    TC/HDL-C ratio calculated at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4

    Time frame: Baseline and Week 6 (end of Phase I)

  19. Percent Change From Baseline in TC/HDL-C Ratio (Phase II)

    TC/HDL-C Ratio calculated at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.

    Time frame: Baseline (Week 6; end of Phase 1) and Week 12 (end of Phase II)

  20. Percent Change From Baseline in LDL-C/HDL-C Ratio (Phase I)

    LDL-C/HDL-C ratio calculated at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4

    Time frame: Baseline and Week 6 (end of Phase I)

  21. Percent Change From Baseline in LDL-C/HDL-C Ratio (Phase II)

    LDL-C/HDL-C Ratio calculated at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.

    Time frame: Baseline (Week 6; end of Phase 1) and Week 12 (end of Phase II)

  22. Percent Change From Baseline in Apo B/Apo A-I Ratio (Phase I)

    Apo B/Apo A-I ratio calculated at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4

    Time frame: Baseline and Week 6 (end of Phase I)

  23. Percent Change From Baseline in Apo B/Apo A-I Ratio (Phase II)

    Apo B/Apo A-I Ratio calculated at Baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.

    Time frame: Baseline (Week 6; end of Phase 1) and Week 12 (end of Phase II)

  24. Percent Change From Baseline in Non-HDL-C/HDL-C Ratio (Phase I)

    Non HDL-C/HDL-C ratio calculated at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4

    Time frame: Baseline and Week 6 (end of Phase I)

  25. Percent Change From Baseline in Non-HDL-C/HDL-C Ratio (Phase II)

    Non HDL-C/HDL-C Ratio calculated at baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.

    Time frame: Baseline (Week 6; end of Phase 1) and Week 12 (end of Phase II)

  26. Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) (Phase I)

    hs-CRP measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4. Baseline and post-baseline measurements were log-transformed in the response vector, with fixed effects for treatment, time and the interaction of time by treatment.

    Time frame: Baseline and Week 6 (end of Phase I)

  27. Percent Change From Baseline in Hs-CRP (Phase II)

    hs-CRP measured at Baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6. Baseline and post-baseline measurements were log-transformed in the response vector, with fixed effects for treatment, time and the interaction of time by treatment.

    Time frame: Baseline (Week 6; end of Phase 1) and Week 12 (end of Phase II)

07

Results

Posted Feb 12, 2014

Participant flow

Phase I
Participant flow — Phase I
MilestonePhase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mgPhase I: Atorvastatin 20 mgPhase I: Rosuvastatin 10 mgPhase II: EZ 10mg+Atorva 10mgPhase II: EZ 10mg + Atorva 20mg [A]Phase II: Atorva 40mgPhase II: EZ 10mg + Atorva 20mg [R]Phase II: Rosuvastatin 20mg
Started12048394400000
Completed11745588800000
Not completed3285600000
Withdrew: Physician decision01000000
Withdrew: Lost to follow-up03600000
Withdrew: Protocol violation03900000
Withdrew: Withdrawal by subject2102900000
Withdrew: Adverse event1111200000
Phase II
Participant flow — Phase II
MilestonePhase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mgPhase I: Atorvastatin 20 mgPhase I: Rosuvastatin 10 mgPhase II: EZ 10mg+Atorva 10mgPhase II: EZ 10mg + Atorva 20mg [A]Phase II: Atorva 40mgPhase II: EZ 10mg + Atorva 20mg [R]Phase II: Rosuvastatin 20mg
Started00028124126234206
Completed00027116121225200
Not completed00018596
Withdrew: Adverse event00001111
Withdrew: Physician decision00000010
Withdrew: Lost to follow-up00012021
Withdrew: Protocol violation00001200
Withdrew: Withdrawal by subject00004254

Outcome measures

PrimaryPercent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I)

LDL-C levels measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4. LDL-C was calculated using the Friedewald method when triglyceride (TG)\<350 mg/dL (3.95 mmol/L) and beta quantification ultracentrifugation when TG≥350 mg/dL (3.95 mmol/L).

Time frame:
Baseline and Week 6 (end of Phase I )
Reported as:
Median · Percentage Change
Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I)
Percentage ChangePhase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mgPhase I: Atorvastatin 20 mgPhase I: Rosuvastatin 10 mg
Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I)-24.8 ± 23.6-10.1 ± 20.8-13.8 ± 22.8
Statistical analysis
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Phase I: Atorvastatin 20 mg · Multiple Imputation Robust Regression · p = <0.001 (The primary hypotheses were tested at 0.045, applying Hochberg's procedure.) · Difference in m-estimates: -12.7 · 95% CI -16.6 to -8.7M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Phase I: Rosuvastatin 10 mg · Multiple Imputation Robust Regression · p = <0.001 (The primary hypotheses were tested at 0.045, applying Hochberg's procedure.) · Difference in m-estimate: -9.1 · 95% CI -12.9 to -5.4M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
SecondaryPercent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase II).

LDL-C levels measured at Baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12). Baseline was defined as the average of the values at Visits 5 and 6. LDL-C was calculated using the Friedewald method when triglyceride (TG)\<350 mg/dL (3.95 mmol/L) and beta quantification ultracentrifugation when TG ≥350 mg/dL (3.95 mmol/L).

Time frame:
Baseline (Week 6) and Week 12
Reported as:
Median · Percentage Change
Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase II).
Percentage ChangePhase II: EZ 10mg + Atorva 20mg [A]Phase II: Atorva 40mgPhase II: EZ 10mg + Atorva 20mg [R]Phase II: Rosuvastatin 20mgPhase II: EZ 10mg+Atorva 10mg
Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase II).-16.4 ± 31.1-8.1 ± 23.3-19.3 ± 32.1-8.4 ± 20.82.4 ± 27.4
Statistical analysis
  • Phase II: EZ 10mg + Atorva 20mg [A] vs Phase II: Atorva 40mg · Multiple Imputation Robust Regression · p = <0.001 (The secondary hypotheses were tested at an adaptive alpha level depending on the hypotheses testing result of the primary hypotheses.) · Difference in m-estimates: -10.5 · 95% CI -15.9 to -5.1M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
  • Phase II: EZ 10mg + Atorva 20mg [R] vs Phase II: Rosuvastatin 20mg · Multiple Imputation Robust Regression · p = <0.001 (The secondary hypotheses were tested at an adaptive alpha level depending on the hypotheses testing result of the primary hypotheses.) · Difference in m-estimates: -9.5 · 95% CI -13.6 to -5.5M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
SecondaryPercentage of Participants That Reach Target LDL-C Level of < 100 mg/dL (Phase I)
Time frame:
Week 6 (End of Phase I)
Reported as:
Number · Percentage of Participants
Percentage of Participants That Reach Target LDL-C Level of < 100 mg/dL (Phase I)
Percentage of ParticipantsPhase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mgPhase I: Atorvastatin 20 mgRosuvastatin 10 mg
Percentage of Participants That Reach Target LDL-C Level of < 100 mg/dL (Phase I)56.3 ± 4.5537.4 ± 2.2343.6 ± 1.64
Statistical analysis
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Phase I: Atorvastatin 20 mg · Logistic Regression Model · p = <0.001 · Odds ratio (or): 2.51 · 95% CI 1.62 to 3.89Logistic regression model included terms for treatment and baseline LDL-C (where baseline LDL-C was fitted as 3 categories based on tertiles)
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Rosuvastatin 10 mg · Logistic Regression Model · p = 0.007 · Odds ratio (or): 1.77 · 95% CI 1.17 to 2.67Logistic regression model included terms for treatment and baseline LDL-C (where baseline LDL-C was fitted as 3 categories based on tertiles)
SecondaryPercentage of Participants That Reach Target LDL-C Level of < 100 mg/dL (Phase II)
Time frame:
Week 12 (End of Phase II)
Reported as:
Number · Percentage of Participants
Percentage of Participants That Reach Target LDL-C Level of < 100 mg/dL (Phase II)
Percentage of ParticipantsPhase II: EZ 10mg + Atorva 20mg [A]Phase II: Atorva 40mgPhase II: EZ 10mg + Atorva 20mg [R]Phase II: Rosuvastatin 20mgPhase II: EZ 10mg+Atorva 10mg
Percentage of Participants That Reach Target LDL-C Level of < 100 mg/dL (Phase II)55.8 ± 4.5334.1 ± 4.2853.5 ± 3.3035.8 ± 3.38NA
Statistical analysis
  • Phase II: EZ 10mg + Atorva 20mg [A] vs Phase II: Atorva 40mg · Logistic regression Model · p = <0.001 · Odds ratio (or): 2.71 · 95% CI 1.55 to 4.73Logistic regression model included terms for treatment and baseline LDL-C (where baseline LDL-C was fitted as 3 categories based on tertiles)
  • Phase II: EZ 10mg + Atorva 20mg [R] vs Phase II: Rosuvastatin 20mg · Logistic Regression Model · p = <0.001 · Odds ratio (or): 2.38 · 95% CI 1.56 to 3.63Logistic regression model included terms for treatment and baseline LDL-C (where baseline LDL-C was fitted as 3 categories based on tertiles)
SecondaryPercentage of Participants That Reach Target LDL-C Level of < 70 mg/dL (Phase I)
Time frame:
Week 6 (End of Phase I)
Reported as:
Number · Percentage of Participants
Percentage of Participants That Reach Target LDL-C Level of < 70 mg/dL (Phase I)
Percentage of ParticipantsPhase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mgPhase I: Atorvastatin 20 mgRosuvastatin 10 mg
Percentage of Participants That Reach Target LDL-C Level of < 70 mg/dL (Phase I)19.3 ± 3.623.0 ± 0.786.6 ± 0.82
Statistical analysis
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Phase I: Atorvastatin 20 mg · Logistic Regression Model · p = <0.001 · Odds ratio (or): 9.46 · 95% CI 4.56 to 19.62Logistic regression model included terms for treatment and baseline LDL-C (where baseline LDL-C was fitted as 3 categories based on tertiles)
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Rosuvastatin 10 mg · Logistic Regression Model · p = <0.001 · Odds ratio (or): 3.90 · 95% CI 2.23 to 6.82Logistic regression model included terms for treatment and baseline LDL-C (where baseline LDL-C was fitted as 3 categories based on tertiles)
SecondaryPercentage of Participants That Reach Target LDL-C Level of < 70 mg/dL (Phase II)
Time frame:
Week 12 (end of Phase II)
Reported as:
Number · Percentage of Participants
Percentage of Participants That Reach Target LDL-C Level of < 70 mg/dL (Phase II)
Percentage of ParticipantsPhase II: EZ 10mg + Atorva 20mg [A]Phase II: Atorva 40mgPhase II: EZ 10mg + Atorva 20mg [R]Phase II: Rosuvastatin 20mgPhase II: EZ 10mg+Atorva 10mg
Percentage of Participants That Reach Target LDL-C Level of < 70 mg/dL (Phase II)18.3 ± 3.530.8 ± 0.8115.4 ± 2.393.0 ± 1.20NA
Statistical analysis
  • Phase II: EZ 10mg + Atorva 20mg [A] vs Phase II: Atorva 40mg · Logistic Regression Model · p = 0.001 · Odds ratio (or): 27.77 · 95% CI 3.64 to 211.83Logistic regression model included terms for treatment and baseline LDL-C (where baseline LDL-C was fitted as 3 categories based on tertiles)
  • Phase II: EZ 10mg + Atorva 20mg [R] vs Phase II: Rosuvastatin 20mg · Logistic Regression Model · p = <0.001 · Odds ratio (or): 7.08 · 95% CI 2.85 to 17.56Logistic regression model included terms for treatment and baseline LDL-C (where baseline LDL-C was fitted as 3 categories based on tertiles)
SecondaryPercent Change From Baseline in Total Cholesterol (TC) (Phase I)

TC measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4

Time frame:
Baseline and Week 6 (end of Phase I)
Reported as:
Median · Percentage Change
Percent Change From Baseline in Total Cholesterol (TC) (Phase I)
Percentage ChangePhase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mgPhase I: Atorvastatin 20 mgRosuvastatin 10 mg
Percent Change From Baseline in Total Cholesterol (TC) (Phase I)-13.6 ± 17.0-6.3 ± 14.1-8.2 ± 14.7
Statistical analysis
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Phase I: Atorvastatin 20 mg · Multiple Imputation Robust Regression · p = <0.001 · Difference in m-estimates: -7.1 · 95% CI -9.7 to -4.4M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Rosuvastatin 10 mg · Multiple Imputation Robust Regression · p = <0.001 · Difference in m-estimates: -5.8 · 95% CI -8.3 to -3.3M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
SecondaryPercent Change From Baseline in Total Cholesterol (TC) (Phase II)

TC levels measured at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.

Time frame:
Baseline (Week 6; end of Phase I) and Week 12 (end of Phase II)
Reported as:
Median · Percentage Change
Percent Change From Baseline in Total Cholesterol (TC) (Phase II)
Percentage ChangePhase II: EZ 10mg + Atorva 20mg [A]Phase II: Atorva 40mgPhase II: EZ 10mg + Atorva 20mg [R]Phase II: Rosuvastatin 20mgPhase II: EZ 10mg+Atorva 10mg
Percent Change From Baseline in Total Cholesterol (TC) (Phase II)-10.2 ± 19.9-2.9 ± 15.7-13.1 ± 22.8-5.0 ± 14.02.2 ± 15.4
Statistical analysis
  • Phase II: EZ 10mg + Atorva 20mg [A] vs Phase II: Atorva 40mg · Multiple Imputation Robust Regression · p = <0.001 · Difference in m-estimates: -6.8 · 95% CI -10.7 to -3.0M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
  • Phase II: EZ 10mg + Atorva 20mg [R] vs Phase II: Rosuvastatin 20mg · Multiple Imputation Robust Regression · p = <0.001 · Difference in m-estimates: -7.4 · 95% CI -10.2 to -4.5M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
SecondaryPercent Change From Baseline in Triglycerides (TG) (Phase I)

TG measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4. Baseline and post-baseline measurements were log-transformed in the response vector, with fixed effects for treatment, time and the interaction of time by treatment.

Time frame:
Baseline and Week 6 (end of Phase I)
Reported as:
Least squares mean · Percentage Change
Percent Change From Baseline in Triglycerides (TG) (Phase I)
Percentage ChangePhase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mgPhase I: Atorvastatin 20 mgRosuvastatin 10 mg
Percent Change From Baseline in Triglycerides (TG) (Phase I)-6.0 (-10.9 to -0.8)-3.9 (-6.5 to -1.2)-1.1 (-3.1 to 0.9)
Statistical analysis
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Phase I: Atorvastatin 20 mg · Constrained Longitudinal Data Analysis · p = 0.466 · Difference in least-squares means: -2.1 · 95% CI -7.8 to 3.5Geometric mean percent changes from baseline were calculated based on back-transformation via exponentiation of the model-based least square means
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Rosuvastatin 10 mg · Constrained Longitudinal Analysis · p = 0.081 · Difference in least-squares means: -4.9 · 95% CI -10.3 to 0.5Geometric mean percent changes from baseline were calculated based on back-transformation via exponentiation of the model-based least square means
SecondaryPercent Change From Baseline in Triglycerides (TG) (Phase II)

TG levels measured at Baseline (Week 6: end of Phase I) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6. Baseline and post-baseline measurements were log-transformed in the response vector, with fixed effects for treatment, time and the interaction of time by treatment.

Time frame:
Baseline (Week 6; end of Phase I) and Week 12 (end of Phase II)
Reported as:
Least squares mean · Percentage Change
Percent Change From Baseline in Triglycerides (TG) (Phase II)
Percentage ChangePhase II: EZ 10mg + Atorva 20mg [A]Phase II: Atorva 40mgPhase II: EZ 10mg + Atorva 20mg [R]Phase II: Rosuvastatin 20mgPhase II: EZ 10mg+Atorva 10mg
Percent Change From Baseline in Triglycerides (TG) (Phase II)-5.9 (-11.0 to -0.4)-3.1 (-8.4 to 2.4)-10.2 (-13.9 to -6.4)-3.2 (-7.3 to 1.2)NA (NA to NA)
Statistical analysis
  • Phase II: EZ 10mg + Atorva 20mg [A] vs Phase II: Atorva 40mg · Constrained Longitudinal Data Analysis · p = 0.466 · Difference in least-squares means: -2.8 · 95% CI -10.2 to 4.7Geometric mean percent changes from baseline were calculated based on back-transformation via exponentiation of the model-based least square means
  • Phase II: EZ 10mg + Atorva 20mg [R] vs Phase II: Rosuvastatin 20mg · Constrained Longitudinal Data Analysis · p = 0.011 · Difference in least-squarres means: -7.1 · 95% CI -12.6 to -1.6Geometric mean percent changes from baseline were calculated based on back-transformation via exponentiation of the model-based least square means
SecondaryPercent Change From Baseline in High-density Lipoprotein-Cholesterol (HDL-C) (Phase I)

HDL-C measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4

Time frame:
Baseline and Week 6 (end of Phase I)
Reported as:
Median · Percentage Change
Percent Change From Baseline in High-density Lipoprotein-Cholesterol (HDL-C) (Phase I)
Percentage ChangePhase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mgPhase I: Atorvastatin 20 mgRosuvastatin 10 mg
Percent Change From Baseline in High-density Lipoprotein-Cholesterol (HDL-C) (Phase I)0.9 ± 11.9-1.3 ± 11.61.0 ± 13.1
Statistical analysis
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Phase I: Atorvastatin 20 mg · Multiple Imputation Robust Regression · p = 0.133 · Difference in m--estimates: 1.7 · 95% CI -0.5 to 4.0M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Rosuvastatin 10 mg · Multiple Imputation Robust Regression · p = 0.610 · Difference in m-estimates: -0.6 · 95% CI -2.7 to 1.6M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
SecondaryPercent Change From Baseline in HDL-C (Phase II)

HDL-C levels measured at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.

Time frame:
Baseline (Week 6; end of Phase I) and Week 12 (end of Phase II)
Reported as:
Median · Percentage Change
Percent Change From Baseline in HDL-C (Phase II)
Percentage ChangePhase II: EZ 10mg + Atorva 20mg [A]Phase II: Atorva 40mgPhase II: EZ 10mg + Atorva 20mg [R]Phase II: Rosuvastatin 20mgPhase II: EZ 10mg+Atorva 10mg
Percent Change From Baseline in HDL-C (Phase II)0.9 ± 14.11.0 ± 16.0-0.8 ± 13.70.0 ± 15.20.0 ± 11.7
Statistical analysis
  • Phase II: EZ 10mg + Atorva 20mg [A] vs Phase II: Atorva 40mg · Multiple Imputation Robust Regression · p = 0.520 · Difference in m-estimates: -1.0 · 95% CI -4.2 to 2.1M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
  • Phase II: EZ 10mg + Atorva 20mg [R] vs Phase II: Rosuvastatin 20mg · Multiple Imputation Robust Regression · p = 0.567 · Difference in m-estimates: -0.7 · 95% CI -3.1 to 1.7M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
SecondaryPercent Change From Baseline in Apolipoprotein B (Apo B) (Phase I)

Apo-B measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4

Time frame:
Baseline and Week 6 (end of Phase I)
Reported as:
Median · Percentage Change
Percent Change From Baseline in Apolipoprotein B (Apo B) (Phase I)
Percentage ChangePhase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mgPhase I: Atorvastatin 20 mgRosuvastatin 10 mg
Percent Change From Baseline in Apolipoprotein B (Apo B) (Phase I)-12.1 ± 20.7-6.1 ± 20.7-7.6 ± 20.1
Statistical analysis
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Phase I: Atorvastatin 20 mg · Multiple Imputation Robust Regression · p = 0.003 · Difference in m-estimates: -5.3 · 95% CI -8.8 to -1.8M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Rosuvastatin 10 mg · Multiple Imputation Robust Regression · p = 0.011 · Difference in m-estimates: -4.3 · 95% CI -7.7 to -1.0M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
SecondaryPercent Change From Baseline in Apo B (Phase II)

Apo-B levels measured at Baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.

Time frame:
Baseline (Week 6; end of Phase 1) and Week 12 (end of Phase II)
Reported as:
Median · Percentage Change
Percent Change From Baseline in Apo B (Phase II)
Percentage ChangePhase II: EZ 10mg + Atorva 20mg [A]Phase II: Atorva 40mgPhase II: EZ 10mg + Atorva 20mg [R]Phase II: Rosuvastatin 20mgPhase II: EZ 10mg+Atorva 10mg
Percent Change From Baseline in Apo B (Phase II)-12.0 ± 26.5-6.3 ± 19.6-14.0 ± 25.1-4.9 ± 21.8-4.0 ± 16.8
Statistical analysis
  • Phase II: EZ 10mg + Atorva 20mg [A] vs Phase II: Atorva 40mg · Multiple Imputation Robust Regression · p = 0.079 · Difference in m-estimates: -4.3 · 95% CI -9.2 to 0.5M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
  • Phase II: EZ 10mg + Atorva 20mg [R] vs Phase II: Rosuvastatin 20mg · Multiple Imputation Robust Regression · p = <0.001 · Difference in m-estimates: -7.7 · 95% CI -11.4 to -4.1M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
SecondaryPercent Change From Baseline in Apolipoprotein A-I (Apo A-I) (Phase I)

Apo-A-I measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4

Time frame:
Baseline and Week 6 (end of Phase I)
Reported as:
Median · Percentage Change
Percent Change From Baseline in Apolipoprotein A-I (Apo A-I) (Phase I)
Percentage ChangePhase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mgPhase I: Atorvastatin 20 mgRosuvastatin 10 mg
Percent Change From Baseline in Apolipoprotein A-I (Apo A-I) (Phase I)-0.6 ± 13.1-1.9 ± 12.51.4 ± 13.0
Statistical analysis
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Phase I: Atorvastatin 20 mg · Multiple Imputation Robust Regression · p = 0.156 · Difference in m-estimates: 1.6 · 95% CI -0.6 to 3.8M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Rosuvastatin 10 mg · Multiple Imputation Robust Regression · p = 0.425 · Difference in m-estimates: -0.9 · 95% CI -2.9 to 1.2M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
SecondaryPercent Change From Baseline in Apo A-I (Phase II)

Apo-A-I levels measured at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.

Time frame:
Baseline (Week 6; end of Phase I) and Week 12 (end of Phase II)
Reported as:
Median · Percentage Change
Percent Change From Baseline in Apo A-I (Phase II)
Percentage ChangePhase II: EZ 10mg + Atorva 20mg [A]Phase II: Atorva 40mgPhase II: EZ 10mg + Atorva 20mg [R]Phase II: Rosuvastatin 20mgPhase II: EZ 10mg+Atorva 10mg
Percent Change From Baseline in Apo A-I (Phase II)1.6 ± 11.91.4 ± 14.1-0.6 ± 14.40.0 ± 16.0-0.7 ± 14.3
Statistical analysis
  • Phase II: EZ 10mg + Atorva 20mg [A] vs Phase II: Atorva 40mg · Multiple Imputation Robust Regression · p = 0.739 · Difference in m-estimates: 0.5 · 95% CI -2.5 to 3.6M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
  • Phase II: EZ 10mg + Atorva 20mg [R] vs Phase II: Rosuvastatin 20mg · Multiple Imputation Robust Regression · p = 0.410 · Difference in m-estimates: -1.0 · 95% CI -3.3 to 1.3M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
SecondaryPercent Change From Baseline in Non-HDL-C (Phase I)

Non-HDL-C measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4

Time frame:
Baseline and Week 6 (end of Phase I)
Reported as:
Median · Percentage Change
Percent Change From Baseline in Non-HDL-C (Phase I)
Percentage ChangePhase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mgPhase I: Atorvastatin 20 mgRosuvastatin 10 mg
Percent Change From Baseline in Non-HDL-C (Phase I)-18.0 ± 22.3-7.9 ± 17.6-11.1 ± 19.8
Statistical analysis
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Phase I: Atorvastatin 20 mg · Multiple Imputation Robust Regression · p = <0.001 · Difference in m-estimates: -10.1 · 95% CI -13.6 to -6.6M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Rosuvastatin 10 mg · Multiple Imputation Robust Regression · p = <0.001 · Difference in m-estimates: -7.6 · 95% CI -10.9 to -4.3M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
SecondaryPercent Change From Baseline in Non-HDL-C (Phase II)

Non-HDL-C levels calculated at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.

Time frame:
Baseline (Week 6; end of Phase I) and Week 12 (end of Phase II)
Reported as:
Median · Percentage Change
Percent Change From Baseline in Non-HDL-C (Phase II)
Percentage ChangePhase II: EZ 10mg + Atorva 20mg [A]Phase II: Atorva 40mgPhase II: EZ 10mg + Atorva 20mg [R]Phase II: Rosuvastatin 20mgPhase II: EZ 10mg+Atorva 10mg
Percent Change From Baseline in Non-HDL-C (Phase II)-17.5 ± 26.1-5.5 ± 16.6-18.1 ± 29.4-6.3 ± 18.5-0.5 ± 17.7
Statistical analysis
  • Phase II: EZ 10mg + Atorva 20mg [A] vs Phase II: Atorva 40mg · Multiple Imputation Robust Regression · p = <0.001 · Difference in m-estimates: -9.3 · 95% CI -14.0 to -4.5M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
  • Phase II: EZ 10mg + Atorva 20mg [R] vs Phase II: Rosuvastatin 20mg · Multiple Imputation Robust Regression · p = 0.001 · Difference in m-estimates: -9.8 · 95% CI -13.5 to -6.2M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
SecondaryPercent Change From Baseline in TC/HDL-C Ratio (Phase I)

TC/HDL-C ratio calculated at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4

Time frame:
Baseline and Week 6 (end of Phase I)
Reported as:
Median · Percentage Change
Percent Change From Baseline in TC/HDL-C Ratio (Phase I)
Percentage ChangePhase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mgPhase I: Atorvastatin 20 mgRosuvastatin 10 mg
Percent Change From Baseline in TC/HDL-C Ratio (Phase I)-14.3 ± 17.9-4.5 ± 16.8-9.0 ± 19.1
Statistical analysis
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Phase I: Atorvastatin 20 mg · Multiple Imputation Robust Regression · p = <0.001 · Difference in m-estimates: -8.1 · 95% CI -11.2 to -4.9M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Rosuvastatin 10 mg · Multiple Imputation Robust Regression · p = 0.001 · Difference in m-estimates: -4.8 · 95% CI -7.8 to -1.9M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
SecondaryPercent Change From Baseline in TC/HDL-C Ratio (Phase II)

TC/HDL-C Ratio calculated at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.

Time frame:
Baseline (Week 6; end of Phase 1) and Week 12 (end of Phase II)
Reported as:
Median · Percentage Change
Percent Change From Baseline in TC/HDL-C Ratio (Phase II)
Percentage ChangePhase II: EZ 10mg + Atorva 20mg [A]Phase II: Atorva 40mgPhase II: EZ 10mg + Atorva 20mg [R]Phase II: Rosuvastatin 20mgPhase II: EZ 10mg+Atorva 10mg
Percent Change From Baseline in TC/HDL-C Ratio (Phase II)-13.5 ± 21.7-6.5 ± 13.9-11.7 ± 23.3-4.0 ± 17.8-1.0 ± 9.6
Statistical analysis
  • Phase II: EZ 10mg + Atorva 20mg [A] vs Phase II: Atorva 40mg · Multiple Imputation Robust Regression · p = <0.001 · Difference in m-estimates: -6.9 · 95% CI -11.0 to -2.8M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
  • Phase II: EZ 10mg + Atorva 20mg [R] vs Phase II: Rosuvastatin 20mg · Multiple Imputation Robust Regression · p = <0.001 · Difference in m-estimates: -6.4 · 95% CI -9.4 to -3.3M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
SecondaryPercent Change From Baseline in LDL-C/HDL-C Ratio (Phase I)

LDL-C/HDL-C ratio calculated at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4

Time frame:
Baseline and Week 6 (end of Phase I)
Reported as:
Median · Percentage Change
Percent Change From Baseline in LDL-C/HDL-C Ratio (Phase I)
Percentage ChangePhase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mgPhase I: Atorvastatin 20 mgPhase 1: Rosuvastatin 10 mg
Percent Change From Baseline in LDL-C/HDL-C Ratio (Phase I)-23.9 ± 23.6-7.1 ± 23.2-14.7 ± 26.9
Statistical analysis
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Phase I: Atorvastatin 20 mg · Multiple Imputation Robust Regression · p = <0.001 · Difference in m-estimates: -13.7 · 95% CI -18.1 to -9.3M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Phase 1: Rosuvastatin 10 mg · Multiple Imputation Robust Regression · p = <0.001 · Difference in m-estimates: -7.8 · 95% CI -11.9 to -3.6M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
SecondaryPercent Change From Baseline in LDL-C/HDL-C Ratio (Phase II)

LDL-C/HDL-C Ratio calculated at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.

Time frame:
Baseline (Week 6; end of Phase 1) and Week 12 (end of Phase II)
Reported as:
Median · Percentage Change
Percent Change From Baseline in LDL-C/HDL-C Ratio (Phase II)
Percentage ChangePhase II: EZ 10mg + Atorva 20mg [A]Phase II: Atorva 40mgPhase II: EZ 10mg + Atorva 20mg [R]Phase II: Rosuvastatin 20mgPhase II: EZ 10mg+Atorva 10mg
Percent Change From Baseline in LDL-C/HDL-C Ratio (Phase II)-20.6 ± 31.4-8.2 ± 20.6-18.2 ± 31.6-7.5 ± 21.5-4.5 ± 22.9
Statistical analysis
  • Phase II: EZ 10mg + Atorva 20mg [A] vs Phase II: Atorva 40mg · Multiple Imputation Robust Regression · p = <0.001 · Difference in m-estimates: -10.4 · 95% CI -15.8 to -4.9M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
  • Phase II: EZ 10mg + Atorva 20mg [R] vs Phase II: Rosuvastatin 20mg · Multiple Imputation Robust Regression · p = <0.001 · Difference in m-estimates: -8.3 · 95% CI -12.5 to -4.2M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
SecondaryPercent Change From Baseline in Apo B/Apo A-I Ratio (Phase I)

Apo B/Apo A-I ratio calculated at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4

Time frame:
Baseline and Week 6 (end of Phase I)
Reported as:
Median · Percentage Change
Percent Change From Baseline in Apo B/Apo A-I Ratio (Phase I)
Percentage ChangePhase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mgPhase I: Atorvastatin 20 mgPhase 1: Rosuvastatin 10 mg
Percent Change From Baseline in Apo B/Apo A-I Ratio (Phase I)-13.0 ± 22.3-4.8 ± 18.9-8.8 ± 23.0
Statistical analysis
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Phase I: Atorvastatin 20 mg · Multiple Imputation Robust Regression · p = <0.001 · Difference in m-estimates: -6.3 · 95% CI -10.0 to -2.5M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Phase 1: Rosuvastatin 10 mg · Multiple Imputation Robust Regression · p = 0.052 · Difference in m-estimates: -3.5 · 95% CI -7.1 to 0.0M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
SecondaryPercent Change From Baseline in Apo B/Apo A-I Ratio (Phase II)

Apo B/Apo A-I Ratio calculated at Baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.

Time frame:
Baseline (Week 6; end of Phase 1) and Week 12 (end of Phase II)
Reported as:
Median · Percentage Change
Percent Change From Baseline in Apo B/Apo A-I Ratio (Phase II)
Percentage ChangePhase II: EZ 10mg + Atorva 20mg [A]Phase II: Atorva 40mgPhase II: EZ 10mg + Atorva 20mg [R]Phase II: Rosuvastatin 20mgPhase II: EZ 10mg+Atorva 10mg
Percent Change From Baseline in Apo B/Apo A-I Ratio (Phase II)-11.2 ± 26.2-6.4 ± 19.4-11.2 ± 27.5-5.4 ± 21.5-6.7 ± 11.3
Statistical analysis
  • Phase II: EZ 10mg + Atorva 20mg [A] vs Phase II: Atorva 40mg · Multiple Imputation Robust Regression · p = 0.024 · Difference in m-estimates: -5.8 · 95% CI -10.8 to -0.8M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
  • Phase II: EZ 10mg + Atorva 20mg [R] vs Phase II: Rosuvastatin 20mg · Multiple Imputation Robust Regression · p = 0.002 · Difference in m-estimates: -6.1 · 95% CI -9.9 to -2.3M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
SecondaryPercent Change From Baseline in Non-HDL-C/HDL-C Ratio (Phase I)

Non HDL-C/HDL-C ratio calculated at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4

Time frame:
Baseline and Week 6 (end of Phase I)
Reported as:
Median · Percentage Change
Percent Change From Baseline in Non-HDL-C/HDL-C Ratio (Phase I)
Percentage ChangePhase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mgPhase I: Atorvastatin 20 mgPhase 1: Rosuvastatin 10 mg
Percent Change From Baseline in Non-HDL-C/HDL-C Ratio (Phase I)-18.9 ± 23.9-6.3 ± 22.8-12.2 ± 25.9
Statistical analysis
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Phase I: Atorvastatin 20 mg · Multiple Imputation Robust Regression · p = <0.001 · Difference in m-estimates: -10.6 · 95% CI -14.9 to -6.4M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Phase 1: Rosuvastatin 10 mg · Multiple Imputation Robust Regression · p = 0.002 · Difference in m-estimates: -6.2 · 95% CI -10.2 to -2.2M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
SecondaryPercent Change From Baseline in Non-HDL-C/HDL-C Ratio (Phase II)

Non HDL-C/HDL-C Ratio calculated at baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.

Time frame:
Baseline (Week 6; end of Phase 1) and Week 12 (end of Phase II)
Reported as:
Median · Percentage Change
Percent Change From Baseline in Non-HDL-C/HDL-C Ratio (Phase II)
Percentage ChangePhase II: EZ 10mg + Atorva 20mg [A]Phase II: Atorva 40mgPhase II: EZ 10mg + Atorva 20mg [R]Phase II: Rosuvastatin 20mgPhase II: EZ 10mg+Atorva 10mg
Percent Change From Baseline in Non-HDL-C/HDL-C Ratio (Phase II)-18.2 ± 29.5-8.8 ± 18.8-16.3 ± 32.3-5.9 ± 23.4-1.9 ± 12.9
Statistical analysis
  • Phase II: EZ 10mg + Atorva 20mg [A] vs Phase II: Atorva 40mg · Multiple Imputation Robust Regression · p = <0.001 · Difference in m-estimates: -9.3 · 95% CI -14.8 to -3.9M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
  • Phase II: EZ 10mg + Atorva 20mg [R] vs Phase II: Rosuvastatin 20mg · Multiple Imputation Robust Regression · p = <0.001 · Difference in m-estimates: -8.4 · 95% CI -12.6 to -4.2M-Estimates, 95% CI, and p-value obtained from a robust regression model with terms for treatment and baseline values, after imputing missing values
SecondaryPercent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) (Phase I)

hs-CRP measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4. Baseline and post-baseline measurements were log-transformed in the response vector, with fixed effects for treatment, time and the interaction of time by treatment.

Time frame:
Baseline and Week 6 (end of Phase I)
Reported as:
Least squares mean · Percentage Change
Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) (Phase I)
Percentage ChangePhase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mgPhase I: Atorvastatin 20 mgPhase I: Rosuvastatin 10 mg
Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) (Phase I)-10.5 (-23.0 to 4.0)-6.6 (-13.6 to 1.0)-9.0 (-14.0 to -3.6)
Statistical analysis
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Phase I: Atorvastatin 20 mg · Constrained Longitudinal Data Analysis · p = 0.613 · Difference in least-squares means: -3.9 · 95% CI -18.9 to 11.1Geometric mean percent changes from baseline were calculated based on back-transformation via exponentiation of the model-based least square means
  • Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg vs Phase I: Rosuvastatin 10 mg · Constrained Longitudinal Data Analysis · p = 0.831 · Difference in least-squares means: -1.5 · 95% CI -15.7 to 12.6Geometric mean percent changes from baseline were calculated based on back-transformation via exponentiation of the model-based least square means
SecondaryPercent Change From Baseline in Hs-CRP (Phase II)

hs-CRP measured at Baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6. Baseline and post-baseline measurements were log-transformed in the response vector, with fixed effects for treatment, time and the interaction of time by treatment.

Time frame:
Baseline (Week 6; end of Phase 1) and Week 12 (end of Phase II)
Reported as:
Least squares mean · Percentage Change
Percent Change From Baseline in Hs-CRP (Phase II)
Percentage ChangePhase II: EZ 10mg + Atorva 20mg [A]Phase II: Atorva 40mgPhase II: EZ 10mg + Atorva 20mg [R]Phase II: Rosuvastatin 20mgPhase II: EZ 10mg+Atorva 10mg
Percent Change From Baseline in Hs-CRP (Phase II)-19.5 (-31.5 to -5.3)-6.4 (-20.2 to 9.8)-10.9 (-20.9 to 0.3)0.7 (-11.2 to 14.2)NA (NA to NA)
Statistical analysis
  • Phase II: EZ 10mg + Atorva 20mg [A] vs Phase II: Atorva 40mg · Constrained Longitudinal Data Analysis · p = 0.187 · Difference in least-squares means: -13.1 · 95% CI -32.6 to 6.4Geometric mean percent changes from baseline were calculated based on back-transformation via exponentiation of the model-based least square means
  • Phase II: EZ 10mg + Atorva 20mg [R] vs Phase II: Rosuvastatin 20mg · Constrained Longitudinal Data Analysis · p = 0.153 · Difference in least-squares means: -11.6 · 95% CI -27.7 to 4.4Geometric mean percent changes from baseline were calculated based on back-transformation via exponentiation of the model-based least square means

Adverse events

Collected over up to 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg—0/120 (0%)0/120 (0%)
Phase I: Atorvastatin 20 mg—3/480 (0.6%)0/480 (0%)
Phase I: Rosuvastatin 10 mg—10/939 (1.1%)0/939 (0%)
Phase II: EZ 10mg+Atorva 10mg—0/28 (0%)0/28 (0%)
Phase II: EZ 10mg + Atorva 20mg [A]—2/124 (1.6%)0/124 (0%)
Phase II: Atorva 40mg—2/124 (1.6%)0/124 (0%)
Phase II: EZ 10mg + Atorva 20mg [R]—5/231 (2.2%)0/231 (0%)
Phase II: Rosuvastatin 20mg—1/205 (0.5%)0/205 (0%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventPhase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mgPhase I: Atorvastatin 20 mgPhase I: Rosuvastatin 10 mgPhase II: EZ 10mg+Atorva 10mgPhase II: EZ 10mg + Atorva 20mg [A]Phase II: Atorva 40mgPhase II: EZ 10mg + Atorva 20mg [R]Phase II: Rosuvastatin 20mg
Myocardial infarctionCardiac disorders0/1200/4801/9390/280/1241/1240/2310/205
Angina unstableCardiac disorders0/1200/4800/9390/280/1241/1240/2310/205
Vitreous haemorrhageEye disorders0/1200/4800/9390/281/1240/1240/2310/205
Chest painGeneral disorders0/1200/4800/9390/281/1240/1240/2310/205
Cerebral infarctionNervous system disorders0/1200/4800/9390/280/1240/1240/2311/205
Coronary artery diseaseCardiac disorders0/1201/4800/9390/280/1240/1241/2310/205
Angina pectorisCardiac disorders0/1200/4800/9390/280/1240/1241/2310/205
Alcohol poisoningInjury, poisoning and procedural complications0/1200/4800/9390/280/1240/1241/2310/205
HyperglycaemiaMetabolism and nutrition disorders0/1200/4800/9390/280/1240/1241/2310/205
Calculus urinaryRenal and urinary disorders0/1200/4800/9390/280/1240/1241/2310/205

Baseline characteristics

Age, Customized
Age, Customized(Participants)Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mgPhase I: Atorvastatin 20 mgPhase I: Rosuvastatin 10 mgTotal
<20 years0011
20 to 29 years0426
30 to 39 years1132539
40 to 49 years165099165
50 to 59 years37170324531
60 to 64 years2787183297
≥65 years39159310508
Sex: Female, Male
Sex: Female, Male(Participants)Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mgPhase I: Atorvastatin 20 mgPhase I: Rosuvastatin 10 mgTotal
Female71253489813
Male49230455734
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Krempf M, Simpson RJ Jr, Ramey DR, Brudi P, Giezek H, Tomassini JE, Lee R, Farnier M. Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey. Lipids Health Dis. 2015 May 19;14:45. doi: 10.1186/s12944-015-0037-y. PubMed 25985907 ↗
  • Bays HE, Averna M, Majul C, Muller-Wieland D, De Pellegrin A, Giezek H, Lee R, Lowe RS, Brudi P, Triscari J, Farnier M. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia. Am J Cardiol. 2013 Dec 15;112(12):1885-95. doi: 10.1016/j.amjcard.2013.08.031. Epub 2013 Sep 21. PubMed 24063830 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Sep 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2014, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2010
First posted
Jun 30, 2010
Start
Jul 2010
Primary completionActual
Sep 2012
CompletionActual
Oct 2012
Results first posted
Feb 12, 2014
Last update
Feb 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01154036
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Jun 30, 2010
Start date
Jul 2010
Primary completion
Sep 2012
Completion
Oct 2012
Results posted
Feb 12, 2014
Last update
Feb 9, 2022

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ezetimibe · Atorvastatin

Start the discussion